Immuneering Reports Strong FY 2025 Results and Positive Pancreatic Cancer Trial Data

Key Facts

1The company reported a 64% overall survival rate at 12 months in its Phase 2a pancreatic cancer trial, significantly exceeding the 35% benchmark.

2The company ended 2025 with $217 million in cash, providing a financial runway into 2029.

3Dosing for the first patient in the pivotal Phase 3 MAPKeeper 301 trial is scheduled for mid-2026.

Immuneering Corporation (Nasdaq: IMRX) reported its full-year 2025 financial results, highlighted by significant clinical progress and a robust balance sheet. The company achieved a 64% overall survival rate at 12 months in its Phase 2a pancreatic cancer trial, more than doubling the industry benchmark of 35%. Financially, Immuneering ended the year with $217 million in cash, ensuring a funding runway that extends into 2029. Looking ahead, the company plans to begin patient dosing for its pivotal Phase 3 MAPKeeper 301 trial in mid-2026. These developments underscore the potential of its lead candidate, atebimetinib, in treating advanced oncology cases. The combination of clinical success and financial stability positions the company well for long-term growth while reducing immediate dilution concerns.